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Besides intensive studies into the synthesis of the complex trans-Hlnd[RuCl(ind)] (Ind indazole)
1, which differs remarkably from the usual method for the complexes of the HL[RuCIL]- type,
competitive products and hydrolysis of this species are described. Stability and pseudo-first-order
rate constant under physiological conditions of complex 1 in comparison with the analogous imida-
zole complex trans-HIm[RuCl(im)] (Im imidaZole) ICR were examined by means of HPLC, UV
and conductivity measurements (ko.(1) 1.55 x 10" s; ko,,(ICR 9.10 x 10 s’l)o An attempt
was made to elucidate the bonding conditions in 1 by studying the reactions of Ru(lll) and the two
N-methyl isomers of indazole. It can be expected that bonding in the unsubstituted ligand should
occur via the N2 nitrogen. The molecular structures of the complex trans-H(1-Melnd)[RuCl(1-Me-
Ind)] x 1HO (1-Melnd---1-methylindazole) 6 and its hydrolysis product in aqueous solution
[RuCl(HO)(1-Melnd)] 7 were determined crystallographically. After anisotropic refinement of F
values by least squares, R is 0.053 for 6 and 0.059 for 7. Both complexes crystallize with four
molecules in a unit cell of monoclinic symmetry. The space group is P2.1/n for 6 with cell dimen-
sions a 10.511A, b 13.87A, c 19.93,, and 98.17 and C2/c for 7 with a 19.90,, b-
10.94A, c 8.490A and I 96.74. The fact that the aqua species 7 could be isolated after dis-
solving 6 in a water/acetone solution confirmed the theory of many Ru(lll) complexes being initially
transformed, under physiological conditions, into aqua complexes in a first and often rate-de-
termining hydrolysis step. Compounds I and ICR are potent antitumor agents which exhibit activity
against a variety of tumor cells and experimental tumor models in animals, including autoch-
thonous colorectal tumors. Clinical studies with I are in preparation.
Introduction
Today the development of ruthenium complexes as an alternative to platiniferous tumor inhibitors is
of special interest-. Ruthenium complexes with the general formula HL[RuCIL], with L nitrogen
hetemcycle, show antitumor activity in different systems in vitro and in vivo and outstanding activity
in an autochthonous colorectal tumor model with a tumor reduction of about 70 % to 90%,-. The
water-soluble anionic complexes are characterized by trans- standing heterocycles. The first com-
plex of the type mentioned above we synthesized was trans-HIm[RuCl,(im)] (ICR), with two imida-
zoles as organic ligands. Now we present the analogous indazole complex trans-Hlnd[RuCl,(ind)]
(1), which shows higher antitumor activity than ICR in many test systems. The structures of ICR
and 1 are shown in Figure 1. trans-Hlnd[RuCl(ind)] (1) is not only active against transplantable
tumors but also in a model system with acetoxymethylmethylnitrosamine (AMMN) induced tumors
in the colon of rats. These autochthonous tumors induced by intrarectal application of this carcino-
gen are highly comparable to human colon tumors in their histological appearance as well as in
their behaviour against chemotherapeutics. The development of such a new type of drug is of
special interest because tumors of the colon account for a high percentage of cancer mortality
today.
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Figure 1. Structures of trans-HIm[RuCl4(im)] ICR and trans-Hlnd[RuCl4(ind)] 1.
Extensive studies have been made into the fact that ruthenium complexes with good antitumor
effects undergo numerous conversions in vivo and are transformed into the species which is active
at the affected area by metabolic processes. Therefore Ru(lll) complexes are better handled as
"prodrugs", which are converted in situ into the corresponding, more labile, species. These com-
plexes are able to dissociate one or more non-nitrogen ligands, which in our case are the reactive
CI leaving groups, to undergo bonding with the target molecule. It is supposed that in the first step
HO-molecules coordinate at the free positions until bonding to a biomolecule. In this paper, the
results of these investigations for complex 1 and its derivatives are reported in comparison with the
hydrolysis of ICR as well as extensive studies into its synthesis. We discuss the structure of the
analogous complex trans-H(1-Melnd)[RuCl(1-Melnd)] x 1HO 6 and its hydrolysis product
[RuCla(HO)(1-Melnd)] 7 with 1-methylindazole as organic ligand L.
Materials and Methods
Materials. "RuCI x 3 HO" was obtained from Degussa (Frankfurt, FRG) and was used after puri-
fication according to methods which are listed in the following section; indazole was provided by
Degussa (Frankfurt / Main), and 1- and 2-methylindazole were produced by reduction of N-substi-
tuted o-nitrobenzylidenamine with lithium aluminium hydride according to the method of Bakke and
Skjervolds.
General instructions. The purification methods for "RuCI x 3 HO" (production of pure Ru(lll)
solutions with different properties) were as follows:
Method I: Diluted ruthenium solution.
8 g (28.34 mmol) of RuCI x 3 H=O were heated for one hour under reflux in 50 ml of 1 N HCI and
ethanol (50 ml). After cooling the dark red solution down to 40C, the alcohol and the produced
acetaldehyde were removed under reduced pressure. The residues were filtered and filled up with
1 N HCI to give a volume of 100 ml. The solution thus obtained contains 28.3 mmol of ruthenium,
which is present in the oxidation state +111 exclusively.
Method I1" Concentrated ruthenium solution.
The procedure is as described under method I, but instead of 1 N HCI concentrated HCI (12 N)
was used.
Method II1" Ruthenium solution in 1 N ethanolic HCI.
The procedure is as described under method I, but instead of 1 N HCI solution 1 N ethanolic HCI
solution was used and preparation is carried out under nitrogen atmosphere. The alcoholic hydro-
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chloric acid was produced by letting HCI gas stream through absolute ethanol. The concentration
was determined by titration against 1 N NaOH.
Complex Syntheses. The preparation of the complexes with indazole, 1-, and 2-methylindazole
as nitrogen ligands can be carried out by the following methods and is highly dependent on exact
reaction conditions. The quantity of the heterobases varies according to the desired products and
the used ligands. With indazole, five different ruthenium complexes could be isolated and charac-
terized, two of them are new types not yet mentioned in the literature. Crystallization of the com-
plexes was difficult because of hydrolysis in most of the suitable solvents. All new compounds
gave satisfactory elemental analyses.
trans-Hlnd[RuCl,(ind)=] (1). General method: Indazole (6.0 g; 51 mmol) was dissolved in 80 ml
of 12 N HCI at 70 C. 20 ml of the Ru(lll) solution (method II) were added to the hot solution and
the mixture was stirred and heated for about 15 min at 80-90 C. An ochre-colored solid separated
from the solution almost immediately. Stirring was continued until ambient temperature was
reached and then the crude material was separated and stirred with water for about two hours to
remove the HCI residues. Then the solid was filtered and washed with ethanol and diethylether and
dried in vacuo. To optimize the yield, the solution was stirred again for several hours at about
80-90C. The purification of the separating solid was carried out as mentioned above. The yield of
the microcrystalline product 1 was: 2.96 g (87 %) (decomp.: 248 C; A= 44.0 [-cmmol-]). Anal.
Calcd for CHNCI,Ru: C, 42.16; H, 3.20; N, 14.05; CI, 23.70; Ru, 16.89. Found: C, 42.20; H,
3.35; N, 13.83; CI, 23.84; Ru, 17.32. IR (cm): v(Ru-CI) 322 s, 295 sh; v(Ru-N) 283 s, 216 s;
5(N-Ru-CI) 179 w; 5(CI-Ru-CI) 151 w.
When using the Ru(lll) solution prepared according to method I, like in the synthesis of the
analogous imidazole complex ICR and all other complexes of the HL[RuClL]-type we have
synthesized so far, the oxo complex 2 was formed instead of the intended complex 1.
(Hlnd),[Ru=OCl(ind)=] (2). General method: Indazole (6.0 g; 51 mmol) was dissolved in 8 N HCI
at 0-5C and 20 ml of the Ru(lll) solution (method I) were added with vigorous stirring. The colour
of the mixture gradually turned into a deep red and after 10 min a dark violet solid began to
precipitate. The reaction mixture was allowed to stand for two days at 5C and then the product
was filtered, washed with HO and dried over POs. The yield of 2 was: 2.44 g (34 %)
(mp: 160-163 C;=
38.5 [cmmol]). Anal. Calcd for CH0NCIORu=: C, 41.53; H, 3.22; N,
13.84; CI, 23.35; Ru, 16.64. Found: C, 41.63; H, 3.39; N, 13.57; CI, 23.58; Ru, 15.75. IR (cm):
v(Ru-O-Ru),,v, 896 m; (Ru-O-Ru) 457 m; v(Ru-CI) 323 s, 293 s; v(Ru-N) 271 s, 222 w;
5(O-Ru-CI), 5(CI-Ru-CI) 194 w, 170 w.
HPLC investigations into complex 2 showed that the samples contained impurities of complex 1.
At room temperature, the sham of 1 is between 10% and 25 %, but at low temperatures in the
range between 0C and 5 C, the share of this competitive product could be kept below 8 %.
(Hlnd)=[RuCls(ind)] x 0.5 H=O (3). General method: Indazole (2.0 g; 17 mmol) was dissolved in
10 ml of 2 N HCI at a temperature of 60-70 C. 20 ml of the Ru(lll) solution (method II) were added
to the warm solution. The red-brown solid precipitated immediately. However, if complex 1 is pro-
duced in a competitive reaction, which is observed as the separation of an ochre-colored solid, the
precipitate must be dissolved again by adding approximately 10 ml of 12 N HCI. The mixture was
then allowed to stand for 24 hours at room temperature. The brown-red product was washed with
water, ethanol and diethylether and dried in vacuo. The yield of 3 was: 1.82 g (50 %) (decomp.:
208-210 C;=
54.2 [cmmol]). Anal. Calcd for CH0NCIRu x 0.5 HO: C, 39.18; H, 3.29; N,
13.05; CI, 27.54; Ru, 15.70. Found: C, 39.23; H, 3.29; N, 13.19; CI, 27.44; Ru, 15.48. IR (cm):
v(Ru-CI) 304 s, 270 sh; v(Ru-N) 218 m.
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(Hlnd)[Ru=OCl0] (4). General method: Indazole (1.30 g; 11 mmol) was dissolved in 90 ml of 1 N
ethanolic HCI. 10 ml of the Ru(lll) solution (method III) were added and the solution thus obtained
was then allowed to stand for 24 hours at room temperature. The dark red crystals were filtered,
wshed with anhydrous ethanol and diethylether and dried in vacuo. The yield of 4 was: 0.93 g
(1%) (decomp.: 193 C; Au= 67.6 [lcm2mol]). Anal. Calcd for CHzNCIoORU: C, 32.05; H,
2.69; N, 10.68; CI, 33.79; Ru, 19.27. Found: C, 32.12; H, 2.72; N, 10.64; CI, 33.32. IR (cm):
v(Ru-O-Ru),,, 888 w; v(Ru-CI) 347 m, 326 s, 312 sh; v(Ru-O-Ru),v, 265 sh; 5(O-Ru-CI),
5(CI-Ru-CI) 201 w, 194 m.
(Hlnd)[RuCl] (5). General method: After dissolving indazole (1.15 g; 9.73 mmol) in 5 ml of 12 N
HCI at 70 C, 10 ml of the Ru(lll) solution (method II) were added with vigorous stirring. The
voluminous red-brown solid separated immediately, and after stirring until room temperature was
reached, the mixture was allowed to stand for 24 hours at this temperature. The microcrystalline
product was washed with HO, with an ethanol/diethylether mixture (1:1) and finally with diethyl-
ether and then dried over PO/CaCI. The yield of 5 was: 0.86 g (45 %) (decomp.: 170 C;
AM= 58.9 [cmmol]). Anal. Calcd for CHNCIRu: C, 37.58; H, 3.15; N, 12.52; CI, 31.69; Ru,
15.06. Found: C, 37.37; H, 3.14; N, 12.34; CI, 30.70. IR (cm-): v(Ru-CI) 305 vs.
trans-H(1-Melnd)[RuCl,(1-Melnd)=] x 1H=O (6). General method: 1-Methylindazole (0.gg;
6.81 mmol) was dissolved in 3.4 ml of 8 N HCI. Then 8.2 ml of the Ru(lll) solution (method I) were
added with stirring. The solution was filtered to remove undissolved residues and after 24 hours the
voluminous ochre-coloured complex 6 was filtered and washed with HO and diethylether. The pro-
duct 6 was dried over P=Os. Yield: 1.15 g (75 %) (mp: 216-219 C;=
32.0 [cmmol-]). The
crude crystals were recrystallized from an acetone / ethanol solution (1:1). X-ray crystallographic
data is listed in Table 1. Anal. Calcd for C4HzNCI4Ru x 1HO: C, 43.78; H, 4.13; N, 12.76; CI,
21.54; Ru, 15.34. Found: C, 43.72; H, 3.93; N, 12.73; CI, 21.96; Ru, 14.81. IR (cm): v(Ru-CI) 335
s, 306 sh; v(Ru-N) 242 w.
trans-[RuCla(H=O)(1-Melnd)=] (7). General method: Complex 6 (0.1 g; 15.2 mmol) was dissolved
in 40 ml of an acetone / water mixture (1:1). The solution was filtered to remove undissolved
residues, and after two days red microcrystals were grown by slow evaporation at room tem-
perature. The yield of 7 was: 56 mg (75 %) (decomp.: 260 C; =
1.2 [-cmmol-]). X-ray
crystallographic data is listed in Table 1. Anal. Calcd for CHN4CIORu: C, 39.24; H, 3.70; N,
11.44; CI, 21.72; Ru, 20.64. Found: C, 39.50; H, 3.75; N, 11.40; CI, 21.03. IR (cm):
3390 s,b; v(HO),,m 3247 vs; v(Ru-OH) 410 w, 856 ms; v(Ru-CI), v(Ru-OH) 340 s,b, 325 sh;
v(Ru-N) 230 w.
(1-Melnd)4[Ru=OCl0] x 2HCl (8). General method as for complex 6, but with concentrated Ru(lll)
solution (method II). The brown-red complex precipitated immediately. The yield of 8 was: 1.05 mg
(38 %) (decomp.: 200-203 C; u= 154.5 [cmmol]). The initial dark orange solution of 8 de-
composes after a few minutes in water and in methanol to give a colourless solution. Anal. Calcd
for C=HNCI0ORu x 2HCI: C, 32.62; H, 3.25; N, 9.51; CI, 36.11; Ru, 17.16. Found: C, 32.73; H,
3.20; N, 9.41; CI, 35.70; Ru, 16.28. IR (cm-) v(Ru-O-Ru),,m 899 w; 5(Ru-O-Ru) 470 m; v(Ru-CI)
298 vs, 314 sh; v(Ru-O-Ru),m 251 w; 5(O-Ru-CI), 5(CI-Ru-CI) 202 w, 192 m.
(2-Melnd)4[Ru=OCl0] x 2HCl (9). General method: 2-MethylindazoleTM (1.0 g; 7.6 mmol) was dis-
solved in 8 N HCI, and 8.8 ml of the Ru(lll) solution (method I) were added at room temperature.
The solution turned into a dark brown, and after adding 2 ml of 12 N HCI and heating the mixture to
80-90 C, a powdery solid began to separate. The product was carefully washed with water and
dried over PO/CaCI. The yield of 9 was: 1.66 mg (56 %) (decomp.: 220-223 C; Au= 153.0
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[cm=mol]). There was no reaction with the preparation method of the 1-methyl-complex (6).
The addition of concentrated HCI and a higher reaction temperature is necessary in the synthesis
of complex 9. Anal. Calcd for C=HNCI0ORu= x 2HCI: C, 32.62; H, 3.25; N, 9.51; CI, 36.11; Ru,
17.16. Found: C, 32.80; H, 3.40; N, 9.13; CI, 35.89. IR (cm): v(Ru-O-Ru),, 901 m; 5(Ru-O-Ru)
470 m; v(Ru-CI) 298 vs,b; v(Ru-O-Ru),n 251 w; 5(O-Ru-CI), 5(CI-Ru-CI) 201 w, 191 m.
Physical measurements. Electronic spectra were recorded on a Perkin Elmer Lambda 9
UVNIS/NIR spectrophotometer in connection with a Perkin Elmer 7300 Professional Computer.
Infrared spectra were recorded with Csl-pellets on a Perkin Elmer 983 G infrared spectrophoto-
meter or a Bruker IFS 113 for spectra in the far IR region. TheH NMR spectra were taken on a
Bruker Ac 200 MHz spectrophotometer and a Bruker AMX 500 MHz spectrophotometer at a tem-
perature of 293 K. Dimethyl-d-sulfoxide was used as solvent. Conductivity measurements were
carried out using an LF191 (WTW) digital conductometer with an LS1/’1"-1.5 platinum electrode in
dimethylformamide (DMF). The cell constant was calibrated to 12.88 mS with 0.1 M KCI solution in
bidistilled water. Measurements were carried out with 0.001 molar solutions at a temperature of
298 K in a water bath. Solvent conductivities were 0.003-0.005 mScm-
for DMF and 0.001-
0.003 mScm-
for HO (bidistilled). HPLC analyses were carried out at 295 K with a Latek P-400
pump, a Merck-Hitachi L-3000 photo-diode-army detector and a Merck-Hitachi chromato-D-2000
integrator. A nucleosil (300 ,,/71; Macherey-Nagel, D0ren, FRG) diole column (250 mm x 8 mm)
was used for chromatography. The mobile phase used consisted of 70 % acetonitrile (Lichmsolv;
Merck, Darmstadt, FRG) and 30 % 5 mM KHPO (pa; Memk, Darmstadt, FRG) in bidistilled water,
pH 4.5. The flow rate was 3 ml/min and UV detection was carried out at 210 nm. The volume of
samples injected onto the column was 20 I1.
X-Ray Crystal Structure Determination. Structures were determined on a Siemens-Stoe AED II
Diffractometer1 at room temperature using Mo K(x radiation ( 0.71073 ) and a graphite
monochromator. Crystal structures were solved by the SHELXTL PLUS program and Patterson
and Fourier methods. Refinement parameters were calculated by the full-matrix-least-squares
method and the atomic form factors were taken from the International Tables. Crystallographic
data for 6 and its aqua complex 7 is summarized in Table 1, atomic positional parameters, bond
lengths and angles are given in Tables 2 and 4 for 6 and in Tables 3 and 5 for 7. The structures of
6 and 7 are shown in Figures 7 and 8.
Results and Discussion
Investigations into the synthesis of the complex Hlnd/[RuCl4(ind)=] (1). Considering the anti-
tumor activity of the complex ICR against tumors of the colon and rectum, which has already been
tested with good success, the analogous indazole complex 1 is of major interest for clinical use
because of its even higher activity. After the failure to produce complex I in the usual way that was
used in the case of the complexes of the HL[RuCl]-type we have synthesized so far and which
have already been described in earlier publicationsTM, the reaction procedures for indazole and
Ru(lll) solutions were intensively studied. First we copied the synthesis for the imidazole complex
ICR and dissolved indazole in 8 N HCI while slightly heating and, after cooling down, the diluted
Ru(lll) solution (method I) was added to the solution with stirring. Then the mixture was examined
over 48 hours by means of HPLC measurements. After ten minutes, the first sample was taken
and immediately put onto the column. The procedure was repeated every ten minutes over a
period of 6 hours. The indazolium cation (Hind/), which is predominant, could be detected at a
retention time of about 3 minutes. Besides, three other product peaks could also be detected. Their
increasing percentages throughout the reaction were determined by peak areas (Fig. 2). The
composition of the reaction mixture measured by HPLC after 24 h showed that three ruthenium
complexes are formed in different shares: A (10 %), B (57 %) and C (33 %).
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In a second experiment, 2 mg of the solid which was isolated from the reaction mixture after 24
hours by filtration, was dissolved in H_O bidest, and separated under the usual conditions on an
analytical column. The HPLC chromatogram of the isolated solid is shown in Fig. 3. The
percentage composition is in good agreement with that of the liquid phase.
%(PEAK AREA)
Figure :2. Percentage increase of products A, B, and C during the reaction of Ru(lll) solution with
indazole in 8 N HCI. (A [RuCl,(ind)]-; B [RuOCIs(ind)]’-; C [RuOCI6(H20)2(ind)2]2).
UV-Absorption
,:,
RT [mia]
Figure 3. HPLC of the solid which was isolated from the reaction mixture after 24 hours. Column"
nucleosil/diole 300 g; eluent: 70 % CHaCN / 30 % 5 mmol KHPO. Dimensions" 250 x 8 mm;
Flow: 3 ml/min.; Detection: UV, 210 nm. (A [RuCl(ind)]; B [RuOCl(ind)]-; C
[RuOCl(HO)a(ind)a]). RT 3.06--, Hind/, RT 10.06--- A, RT 11.60--- B, RT 13.19--- C.
The different fractions were collected, the solvent removed under reduced pressure, dried in
vacuo, and then observed by means of UV-, IR- and H NMR spectroscopy. By making a com-
parison with the IR spectra of pure KHPO, the IR absorptions caused by residues of the added
buffer could be assigned. The H NMR measurements were carried out in DO or in [d6]DMSO to
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distinguish between the presence and absence of an aqua complex. The signal at a retention time
of about three minutes can undoubtedly be assigned to the Hind* cation by means of comparative
UV measurements with free indazole. Also, the H NMR of this fraction shows the characteristic
chemical shifts of the indazolium cation Hind (5 8.04[s, 1H, 3-H]; 7.74[d, 1H, 4-HI; 7.52[d, 1H,
4-HI; 7.33[t, 1H, 5-HI; 7.09[t, 1H, 6-HI. As expected, no highfield-shifted signals caused by anionic
ruthenium-bonded species can be observed.
The following structures could be resolved for the complexes A, B and C:
A:
B:
[RuCl,(ind)]- (anion of complex 1)
[RuOCl(ind)]" (anion of complex 2)
CI.! Cl
Cl
u
’Cl
H
N Ru 0 --’Ru
C: [RuOCl(HO)(ind)]
c, /c c /c
N IRu 0 "-’-Ru N
H,O \ Cl \
Cl OH=
A comparison of the IR spectra and the UV spectra in anhydrous methanol makes it definite that
the component C is not present in the isolated solid, but is produced out of the bridged oxo-
complex B in water by substitution of the CI anions: there are no IR absorptions, which should be
registered if an aqua complex existed, and the UV spectra show no evidence of the presence of
component C. Only if water is added do the UV spectra of the solid product and the reaction
solution become identical. Besides these facts, the reproducibly constant results of the analytical
data prove the composition of the mixture "ABC" to consist of 10-25 % A: Hlnd*[RuCl,(ind)]- (1)
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and 75-90 % B: (Hlnd+)[RuOCIs(ind)] (2). If the bis-aqua complex C: (Hlnd*)[RuOCI6(HO)-
(ind)]
2 was present in the solid with an average sham of at least 30 %, which is indicated by HPLC
experiments, the calculated value for carbon would be 1-1.5 % higher and the nitrogen value would
be about 0.5 % lower.
Finally we succeeded in transforming the product mixture into the pure complex I by treating it with
concentrated HCI at a raised reaction temperature. For that, 60 ml of 12 N HCI in portions of 10 ml
were given to the reaction mixture over a period of 6 hours. A sample for HPLC was taken each
time before adding the acid. The addition of the acid lead to a dramatic change in the composition
of the solution. The results are summarized in Fig. 4.
ml HCI
Figure 4. Difference in percentage composition of the reaction solution of complex I with addition
of conc. HCI. (A [RuCl,(ind)]; B [RuOCl(ind)]; C [RuOCl(HO)(ind)]).
After adding 10 ml of HCI, the concentration of the oxo-bridged species, which had been
predomi’nant in the violet solution up to this point, decreased. The percentage composition after
(a)
UY-Absorpdon
C
l.-Absorptlon
RT (mini RT [mini
Figure 5a. HPLC of the isolated product after the addition of conc. HCI (A anion of 1). (A [Ru-
Cl,(ind)]; B [RuOCl(ind)]"; C [RuOCl(HO)(ind)]). The peak at RT ca. 3 min. is Hind*.
Figure 5b. HPLC of the isolated product after further treatment with conc. HCI (A anion of 1). (A
[RuCl,(ind)]; B [RuOCl(ind)]). The peak at RT ca. 3 min. is Hind/.
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dropping 20 ml of the acid into the reaction mixture leaves merely 8 % of this product. In contrast,
the concentration of the desired complex 1 increased and after the addition of 60 ml of HCI it
prevailed in the solution, which at that time had a brown colour. At the beginning of the addition the
aqua complex C reacted with a slight increase in its concentration, but when further raising the CI
concentration, its formation becomes increasingly hindered. This could be seen in further HPLC
investigations. The beige-coloured solid which had formed throughout the addition of the 12 N HCI
was separated by filtration, washed with HO and ethanol/diethylether (1:1) and dried in vacuo.
The HPLC of this product is shown in Fig. 5a. It is evident that complex 1 provides the main pro-
duct after the treatment with concentrated HCI. Disturbing residues of the oxo-bridged complex 2
and the aqua complex C, which forms out of 2, could be avoided by further treatment of the solid
product with 6 N HCI at 90 C. A HPLC chromatogram of this product after usual purification shows
nearly complete transformation (Fig. 5b). It could be proved that complex I can be made available
from the oxo complex 2 by raising the temperature and adding concentrated HCI. This knowledge
lead us to the general method for the synthesis of 1, which turns out in a remarkably high purity
and which is described in the section dealing with complex synthesis.
Bonding in complex 1. Bonding conditions in complex 1 were elucidated by studying the inter-
actions between ruthenium(Ill) and the two N-methyl isomers of indazole. In a neutral or acid
solution, the indazole molecule exists in a mesomer equilibrium: the five-membered ring of the
indazole can achieve bonding to the metal with its N-1 or with the N-2 nitrogen. To clarify the
situation, both N-methyl derivatives were synthesized in high purity according to the method of
Bakke and SkjervoldTM. While in the case of the 1-methyl derivative the complex trans-H(1-Me-
Ind)[RuCl,(1-Melnd=)] (6) could easily be prepared according to our usual method for complexes of
the HL[RuClL=]-type, the 2-methylindazole did not show any tendency towards binding to the
metal, even if the parameters of the reaction (molar proportions, temperature, pH, time of reaction)
were altered. Only the oxo-species (2-MelndH)[RuOCl0] x 2 HCI (9) could be obtained when a
concentrated Ru(lll) solution was used. So it can be expected that the unsubstituted indazole in
complex 1 is linked to the ruthenium through the N2-nitrogen.
HPLC investigations into the solution chemistry of 1 in comparison with ICR. HPLC is an
important method to prove the purity of a new drug before it can undergo clinical studies. We in-
vestigated the hydrolysis reactions of the two active compounds 1 and ICR, and the newly formed
hydrolysis products were examined. Stability of the complexes in physiological saline was observed
by means of HPLC over a period of two days and by conductivity measurements. While the de-
composition of ICR is about 4 % per hour, that of [RuCI4(ind)] 1 is less than 0.9 % per hour. The
pseudo-first-order rate constant of hydrolysis of ICR at 22C was determined to be 9.10 x 10 s
and for complex 1, it is 1.55 x 10 s Half-lifes were calculated to be 12.7 hours in the case of ICR
and 74.3 hours in the case of 1. These results are in agreement with experiments carried out under
slightly changed conditions1.
The hydrolysis of ICR causes the formation of three new products while in the case of the indazole
complex there is only one. The hydrolysis products were analysed by comparative HPLC measure-
ments, UV spectroscopy and conductivity measurements. The main product of the hydrolysis of
ICR is the neutral complex [RuCl(im)], which appears at a retention time of about three minutes.
This could be proved by comparative UV measurements with the pure trisimidazole complex, which
we had already been able to synthesize. UV detection was carried out at 336 nm, because the
characteristic absorption of [RuCl(im)] in water is expected at this value. Under the experimental
conditions in the HPLC measurements (mobile phase: 70 % acetonitrile/30 % 5 mmol KHPO4),
this band is shifted to 346 nm in the case of [RuCl(im)] as well as for the HPLC-fraction at about
three minutes retention time. After 24 hours the trisimidazole complex is the major hydrolysis
product in the solution with a share of about 60 %. The two other hydrolysis products are likely to
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be aqua complexes having as they do an absorption band at about 360 nm, which is characteristic
of the CI substitution in the complex transformation from trans-H(1-Melnd)[RuCl(1-Melnd=)] x
1HO 6 to the aqua species [RuCl(HO)(1-Melnd)] 7. The composition of the ICR solution after 5
min, 12 hours and 24 hours is shown in Fig. 6.
80-
aqua complex aqua complex
uncharged Him+ charged [RuCI3(im)3]
2,59 3 3,23 3,45
Retention time [mini
after dissoluln Idter 12 hours after 24 houll
Figure 6. Peak areas in the HPLC experiment of the four hydrolysis products of ICR after dis-
solution, 12 and 24 hours. (The intact [RuCl(im)=] is not shown.)
The concentration of the cation Him decreases in accordance with the formation of the tris-
imidazole complex. The ionic aqua complex [RuCl=(HO)(im)]* is expected at a higher retention
time than the neutral aqua species [RuCl(H=O)(im)]. On the other hand, a characteristic feature of
the hydrolysis of the indazole complex 1 is that no trisindazole complex is formed. This could be
confirmed by experimental work. The trisindazole complex could not be obtained, not even through
modification of the synthesis of the analogue [.RuCl(im)]. This fact seems to be important in view
of the remarkably high stability of 1 in the hydrolysis experiments. The HPLC investigations into
this complex have shown that only one product is formed over a period of 10 hours. The evaluation
of UV- and conductivity measurements suggests that this product is probably an aqua complex.
UV spectroscopy and conductivity measurements. In dimethylformamide, ICR equals a 1:1
electrolyte with "slow" cations and anions ( =
52 cmmol
1 at 25 C). Dissolved in water (pH
6.0), it also equals a 1:1 electrolyte, with the molar conductivity A increasing over the time of
measurement from 68 Pzcmmol-
to 143 zcmmol This increase can be attributed to a relative-
ly slow exchange of a CI ion forHO and the simultaneous formation of an aqua complex. Since CI
itself has a higher conductivity than the complex anion, the molar conductivity increases:
HIm/[RuCl,(im)]- + HO ---) [RuCl(HO)(im)] + Him* + CI-
However, prolonged observation periods over 2 days showed that conductivity still increases very
slowly up to values in the range of 2:1 electrolytes. This can be attributed to the formation of
another aqua complex, with two chloride ions replaced by water. The formation of a trisimidazole
complex, which is responsible for the lowered pH of 4.2 of ICR in aqueous solution, could be a
second possibility and is in good agreement with the results of the HPLC investigations:
HIm/[RuCl,(im)] + HO ---) [RuCl(im)] + HO* + Cl
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The molar conductivity of the isolated neutral trisimidazole complex is 0.8 cmmol4 in DMF and
9.9 4cmmol4 in water.
The formation of compound [RuCla(im)a] is further elucidated by UV measurements over a hydro-
lysis period of 14 hours at ambient temperature. We observed UV absorption directly after dis-
solving ICR in water and during 14 hours of hydrolysis respectively. When comparing the results
with the absorption spectrum of [RuCl(im)a] in water, the transformation can be seen. The ab-
sorption at 347.4 nm, which is characteristic of ICR, is continuously shifted to 336 nm, which is
identical with the characteristic absorption band of the pure trisimidazole complex.
As expected, the molar conductivity of the complex Hlnd/[RuCl(ind)] (1) in DMF equals a 1:1
electrolyte (44 4cmmol4). This value remained almost constant over 24 hours. When the com-
plex is dissolved in water, it shows, from the very beginning, high molar conductivity (307
4cmmol4), which increases very slightly to 360 lcmmol4 after 24 hours.
Molecular structures of the complexes 6 and 7. The initial formation of aqua complexes in the
hydrolysis reaction of complex type HL[RuCI4] could be confirmed by the isolation of complex 7,
which is produced from complex 6 dissolved in an aqueous medium. We could crystallize both
compounds and resolve the X-ray crystal structures, which are shown in Figs. 7 and 8. Because of
the fact that the aqua species 7 is formed out of complex 6 in a hydrolysis reaction in which a HO
molecule is substituted for a CI ligand, a comparative examination of these two compounds seems
reasonable. In both cases, the ruthenium is placed in the center of a slightly distorted octahedron,
in which the two trans-standing 1-methylindazoles are arranged in the axial positions (6:
N(1)-Ru(1)-N(2)" 179.8; 7: N(2)-Ru(1)-N(2a)" 174.3), and the four CI atoms in complex 6 are in
the equatorial positions, which in the case of complex 7 are occupied by three CI atoms and the
HO molecule. Bonding to the metal is via the N2-nitmgen of the organic ligand. Compound 6
crystallizes with four molecules in the unit cell of space group P2.1/n, while in the aqua species 7
the four molecules are in a unit cell of space group C2/c (see Tables 1 and 2).
Cll 8
c7
c14
N2
CI1
CI2
CI4
CI3
N1
Cl c6
c2 c5
Figure 7. Molecular structure of the complex anion [RuCl,(1-Melnd)]- of 6.
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Table 1. Crystal Data, Data Collection and Refinement Parameters for trans-H(1-Melnd)-
[RuCl,(1-ielnd)] (6)and trans-[RuCl(HO)(1-ielnd)] (7)
complex 6 7
formula CHzNCIRu x 1HO CHNCIORu
fw 686.46 489.83
space group P2.1/n C2/c
unit cell: a: 10.511 a: 19.90
a, b, c [,], l] [o] b: 13.87, l 98.17 b: 10.94, I 96.74
c: 19.93 c: 8.490
volume [] 2876.1 1835.6
Z 4 4
densy [cm] 1.58 1.77
F(000) 1396 980
cwstal size [mm] 0.6 x 0.6 x 0.95 0.05 x 0.1 x 0.35
cwstal system monoclinic monoclinic
absorption [cm
4 9.4 1.29
radiation, MoK 0.71073 0.71073
sn technique e/2e
max. 2C [o] 48.5 50
h, k, krange +13, +17, 24 23, +12, +10
obsewed reflections 4782 1709
reflections with 1>2. (I) 2407 770
No. of arameters 69
R, Rw 0.053, 0.048 0.059, 0.048
goodne of fit 1.75 1.56
residual electron densi [e/A] 1.48 1.69
C6a
a
)C4a
Figure 8. Molecular structure of 7.
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Table 2. Atomic Positional Parameters (xlO)‘ and Equivalent Isotropic Displacement Pare-
meters (x 10) of complex 6
atom x y z B,(A)"
Ru(1 4950(1 1863(1 2345(1 33(1
C1(1) 4094(2) 2979(2) 1496(1) 45(1)
C1(2) 4439(3) 613(2) 1518(1) 52(1)
C1(3) 5794(2) 754(2) 3189(2) 56(1)
Ci(4) 5457(2) 3097(2) 3151(1) 53(1)
N(1) 6770(6) 1928(6) 2022(4) 38(3)
N(2) 3131 (6) 1799(6) 2670(4) 37(3)
N(3) 7460(8) 2715(6) 1843(4) 37(3)
N(4) 2448(7) 1013(6) 2852(4) 39(3)
C(1) 8570(9) 1389(9) 1658(5) 41 (4)
C(2) 9625(10) 868(9) 1485(6) 56(5)
C(3) 10592(10) 1390(10) 1261 (6) 54(5)
C(4) 10548(10) 2418(10) 1227(6) 62(6)
C(5) 9541(9) 2943(8) 1399(5) 45(4)
C(6) 8551 (10) 2407(8) 1619(5) 42(5)
C(7) 1314(9) 2323(8) 3032(5) 35(4)
C(8) 268(9) 2836(7) 3211(5) 42(4)
C(9) -723(10) 2309(10) 3411 (6) 55(5)
C(10) -666(10) 1302(10) 3452(6) 56(5)
C(11) 329(10) 764(9) 3283(5) 54(5)
C(12) 1349(9) 1315(8) 3075(5) 35(4)
C(14) 2461 (9) 2570(7) 2772(5) 39(4)
C(13) 7433(9) 1134(8) 1907(5) 40(4)
C(17) 2754(10) 3(7) 2734(6) 58(5)
C(18) 7143(9) 3713(7) 1981(6) 55(5)
N(5) 2258(10) 7992(10) 275(5) 74(5)
N(6) 3238(10) 8292(11) -61 (5) 89(6)
C(21) 2251(15) 7041(14) 252(7) 83(7)
C(22) 1412(15) 6394(16) 503(8) 108(9)
C(23) 1588(23) 5466(19) 396(11) 141(13)
C(24) 2592(24) 5081(19) 62(11) 157(15}
C(25) 3402(18) 5739(18) -191(9) 121(11)
C(26) 3220(14) 6707(15) -83(7) 82(7)
C(27) 3867(13) 7575(13) -271 (7) 85(7)
C(28) 1463(13) 8710(12) 538(7) 125(9)
C(31) 2512(15) 1823(14) -194(8) 141(11)
C(32) 3032(22) 901(16) -435(10) 171(15)
0(33) 3455(16) 232(10) -5(7) 200(9)
"the estimated standard deviations are shown in parentheses.
The CI-Ru-CI angles in the complex anion of 6 are 179.8 (CI(1)-Ru(1)-CI(3)) and 179.6
(CI(2)-Ru(1)-CI(4)), which differs only negligibly from linearity considering the Esd’s. In the case of
the neutral species 7, only one angle with 180 could be observed (CI(2)-Ru(1)-O(1)). A re-
markable deviation from linearity could be observed for the angle CI(1)-Ru(1)-CI(la): 172.6, which
is forced by steric hindrance of the methyl groups. It can be assumed that the Cl-atoms C1(1) and
Cl(la), which approach the HO molecule, form H-bridges between the protons of the H20 and the
free electron pairs of the neighbouring chlorines, which would stabilize the aqua complex 7. But
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this cannot really be proved with certainty because there is only a slight increase in the bond
lengths (Ru-CI(1) and Ru-Cl(la)" 2.356 A) compared to the Ru-CI(2) bond (2.304 ,), which is not
in’ olved in H-bridging.
Table 3. Atomic Positional Parameters (x 10) and Equivalent Isotropic Displacement Para-
meters (x 10) of complex 7
atom x y z B(A)
Ru(1) 0 3201 (2) 2500 29(1)
C1(1) 663(2) 3340(4) 382(3) 49(1)
C1(2) 0 1095(5) 2500 49(2)
0(1) 0 5129(15) 2500 52(6)
N(1 -1039(5) 2657(9) -507(11) 40(3)
N(2) -895(4) 3297(1 O) 911(1 O) 37(3)
C(1) -1402(6) 4025(11) 1122(14) 36(3)
C(2) -1915(6) 3891 (11) -232(14) 35(3)
C(3) -2582(7) 4356(12) -608(15) 47(4)
C(4) -2970(7) 3901(12) -1954(15) 49(4)
C(5) -2710(6) 3041 (13) -2846(14) 47(4)
C(6) -2072(6) 2579(11) -2546(14) 45(4)
C(7) -1680(6) 2999(12) -1162(13) 39(3)
C(8) -677(6) 1642(12) -1034(15) 59(4)
"the estimated standard deviations are shown in parentheses.
Table 4. Selected Bond Distances (A) and Angles (deg) of complex 6; Not including the dis-
ordered cation.
Bonds Length" Bonds Angles
Ru(1 )-C1(1 2.373 (3) C1(1 )-Ru(1 )-C1(2) 87.5(1
au(1 )-C1(2) 2.400 (3) C1(1 )-Ru(1 )-C1(3) 179.8(1)
au(1 )-C1(3) 2.359 (3) CI(2)-Ru(1)-CI(3) 92.5(1)
au(1)-Cl(4) 2.355 (4) CI(1)-Ru(1)-CI(4) 92.2(1)
au(1 )-N(1) 2.105 (7) CI(2)-Ru(1)-CI(4) 179.6(1)
Ru(1 )-N(2) 2.107 (7) CI(3)-Ru(1)-CI(4) 87.8(1)
N(1)-N(3) 1.385 (12) CI(1)-Ru(1)-N(1) 91.4(2)
N(1)-C(13) 1.341 (13) CI(2)-Ru(1)-N(1) 86.9(2)
N(2)-N(4) 1.380 (12) CI(3)-Ru(1)-N(1) 88.8(2)
N(2)-C(14) 1.313 (13) CI(4)-Ru(1)-N(1) 92.9(2)
N(3)-C(6) 1.357 (14) CI(1)-Ru(1)-N(2) 88.8(2)
N(3)-C(18) 1.459 (13) CI(2)-Ru(1)-N(2) 93.2(2)
N(4)-C(12) 1.362 (13) CI(3)-Ru(1)-N(2) 91.0(2)
N(4)-C(17) 1.463 (13) CI(4)-Ru(1)-N(2) 87.0(2)
N(1)-Ru(1 )-N(2) 179.8(4)
Ru(1 )-N(1 )-N(3) 130.1 (6)
Ru(1 )-N(1)-C(13) 122.3(7)
N(3)-N(1)-C(13) 107.4(7)
Ru(1 )-N(2)-N(4) 130.0(6)
Ru(1)-N(2)-C(14) 122.9(7)
’Numbers in parentheses are estimated standard deviations (Esd’s) in the least significant digit
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The N-Ru-N angle in 6 amounts to 179.8. In 7, the bond angle is about 174, a slight reduction in
comparison to 6. The C atoms C(1) and C(la) are shifted towards the center, and an optimal
sterical positioning respective of the methyl groups on the opposite side is the result. There is a
slight reduction of the CI(la)-Ru(1)-CI(1) and N(2a)-Ru(1)-N(2) axes towards the HO. Considering
the orientation of the CI-Ru-CI angles, a similar development can be observed: In compound 6 the
CI(1)-Ru(1)-CI(2) and CI(3)-Ru(1)-CI(4) angles are 87.6 and the angles CI(2)-Ru(1)-CI(3) and
CI(1)-Ru(1)-CI(4) are both 92.4. In contrast to this, the angles in 7, which surround the HO, are
reduced to 86.3 (Cl(la)-Ru(1)-O(1)), (CI(1)-Ru(1)-O(1)). The angles on the opposite side are both
still 93.7 ((CI(2)-Ru(1)-CI(1)) and (Cl(2)-Ru(1)-Cl(la)).
Table 5. Selected Bond Distances (,) and Angles (deg) of complex 7; Not including the dis-
ordered cation.
Bonds Length" Bonds Angles
Ru(1)-CI(1) 2.356 (4)
Ru(1)-CI(2) 2.304 (6)
Ru(1)-O(1) 2.109 (17)
Ru(1 )-N(2) 2.107 (8)
Ru(1)-CI(1A) 2.356 (4)
Ru(1)-N(2A) 2.107 (8)
N(1)-N(2) 1.393 (13)
N(1)-C(7) 1.382 (14)
N(1)-C(8) 1.424 (17)
N(2)-C(1) 1.315 (15)
C1(1 )-Ru(1)-C1(2) 93.7(1
C1(1 )-Ru(1 )-O(1 86.3(1
C1(2)-Ru 1 )-O(1 180.0(1
CI(1)-Ru(1)-N(2) 90.9(3)
CI(2)-Ru(1)-N(2) 92.8(3)
O(1 )-Ru(1)-N(2) 87.2(3)
C1(1 )-au(1 )-C1(1 A) 172.6(2)
C1(2)-Ru(1)-C1(1 A) 93.7(1
O(1 )-Ru(1)-CI(1 A) 86.3(1
N(2)-Ru(1)-CI(1 A) 88.8(3)
C1(1 )-Ru(1 )-N(2A) 88.8(3)
CI(2)-Ru(1)-N(2A) 92.9(3)
O(1 )-Ru(1)-N(2A) 87.2(3)
N(2)-au(1 )-N(2A) 174.3(6)
Ci(1A)-Ru(1)-N(2A) 90.9(3)
Ru(1 )-N(2)-N(1) 127.0(7)
Ru(1)-N(2)-C(1) 123.2(8)
"Numbers in parentheses are estimated standard deviations (Esd’s) in the least significant digit
The Ru(1)-O(1) bond in 7 is shorter (2.109 A) than the Ru-CI bonds, which in both compounds are
between 2.355 and 2.400 . The inclusion of a water molecule has no influence on the Ru-N bond
lengths, which are on average 2.107 A and, taking the Esd’s into account, absolutely identical.
This shows that in accordance with our investigations into the solution chemistry of compound 6
the formation of an aqua complex in a first hydrolysis step does not reduce the stability of the
organic ligands and the substitution of another CI leaving group is likely to occur to give the
bis-aqua complex.
Biological tests. After the successful synthesis of the indazole complex I with good yields and the
necessary high purity, the positive results in biological test systems could be confirmed. Fig. 9
shows the results of the therapy of autochthonous colorectal tumors with complex 1 along with
cisplatin, 5-fluorouracil and ICR, which has been the most active ruthenium species until now. The
257Vol. 3, No. 5, 1996 Synthesis, Characterization and Solution Chemistry
antitumor activity could even be surpassed with the indazole complex 1, which effected a tumor re-
duction up to 90%. The 1-methyl complex 6 achieved similar T/C-values as 1 in the P388 leu-
kemia. In this test system, complex 3 recently reached a good T/C-value of 160 % using a single
dose of 75 mg/kg (0.116 mmol/kg) on three subsequent days after tumor transplantation.
T/C I%1
130
120
110
1G0
90
80
70
6O
5O
t.0
30
2O
10
Cisain 5-FU ICR Hlnd[RuCl,(ind=)]
Dose (mg/kg) 1.5 40 7 13
mmol/kg 0.0049 0.066 0.015 0.022
Figure 9. Test results of ICR and trans-Hlnd[RuCl(ind)] 1 in autochthonous colorectal tumors of
the rat, compared to cisplatin and 5-fluorouracil. Doses were applied twice a week over ten weeks.
The reduction of tumor volume represented by the shaded columns is statistically significant
compared to the control group.
Concluding Remarks. The galenic behaviour of water-soluble ruthenium complexes is easier to
manage, because adjuvants are not necessary in parenteral clinical applications. Furthermore the
pseudo-first-order rate constants under physiological conditions show that these ruthenium com-
pounds are sufficiently stable for intravenous infusion. This is a considerable advantage for later
administration in the clinic. Another point is that freshly prepared solutions of ICR do not inhibit
DNA polymerisation, whereas aged solutions, which had enough time to form aqua complexes, are
able to inhibit DNA polymerisation to a high extent. This makes it likely that many of the
ruthenium compounds are only "prodrugs" and hydrolysis inside the tumor cell is necessary for
activation.
As part of our program to synthesize water-soluble tumor-inhibiting ruthenium complexes, we have
developed a synthesis for 1 with sufficient yield and high purity. The complex shows higher anti-
tumor activity in all test systems than ICR, which has been the most active compound so far. The
aquation of the anticancer complexes ICR, and 1 were studied extensively by means of UV-, IR-
and NMR-spectmscopy as well as HPLC- and conductivity measurements. The data obtained
shows that these compounds undergo aquation in aqueous solution, forming different hydrolysis
products. For ICR we observed the formation of a neutral complex [RuCl(im)] as well as mono-
aqua- and diaqua adducts. Due to the formation of the trisimidazole complex, the [RuCI4(im)]
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anion decreases continuously throughout hydrolysis. In contrast, complex 1 shows no tendency
towards forming a trisindazole complex. The halflife of 1 was calculated to be 74.3 hours.
In the case of aquation of active complex 6, we could resolve the resulting monoaqua species 7
crystallographically as well as the initial complex 6. For the RuClL-type prodrugs, this is the first
time that a hydolysis product could be isolated to enrich the discussion of the relationship between
the mode of action and structure. In case preclinical antitumor activity in colorectal tumors can be
confirmed in the clinic, this would mean a considerable progress for the chemotherapy of cancer.
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